核子医学市场－全球产业规模、份额、趋势、机会及预测（按类型、诊断核子医学、治疗核子医学、应用、最终用户、地区和竞争格局划分），2021-2031年

全球核子医学产业预计将从2025年的101.9亿美元显着成长至2031年的193.4亿美元，复合年增长率（CAGR）达11.27%。这个专业医学领域利用放射性药物评估生理过程，并透过标靶分子介入来治疗疾病。推动市场成长的主要因素是全球人口快速老化以及由此导致的癌症和心血管疾病等慢性病发病率上升，这些疾病需要高度精准的诊断和治疗能力。这些流行病学和人口统计趋势确保了对核医学影像和放射性核素治疗的持续需求，使其区别于暂时的市场趋势。

儘管该行业潜力巨大，但在供应链可靠性方面仍面临严峻挑战，尤其是诊断所需的短寿命放射性同位素的持续供应。这些关键材料的生产严重依赖数量有限的老旧研究核子反应炉，使得供应链极易受到物流中断的影响。欧洲核子医学会（Nuclear Medicine Europe）指出，2024年底计画外的核子反应炉维护可能导致关键诊断用同位素发生器供不应求40%，凸显了全球分销体系的脆弱性。

市场驱动因素

治疗性诊断（治疗诊断学）和精准医疗的快速发展是市场扩张的主要驱动力，推动产业从简单的​​诊断影像转向综合治疗策略。这种将诊断生物标记与治疗性放射性同位素结合的调查方法，在肿瘤学领域取得了显着的商业性成功，尤其是在前列腺癌和神经内分泌肿瘤的治疗方面。领先的放射性配体疗法的优异表现证明了这一趋势的强劲经济实力。例如，诺华公司在2024年第三季财报中揭露，其前列腺癌药物Pulvict的全球销售额在该季度达到3.86亿美元，较去年同期成长50%。因此，各大製药公司正迅速加大对该领域的投资。例如，百时美施贵宝公司于2024年2月以约41亿美元收购了RaizeBio公司，以确保其基于锕系元素的放射性药物产品线，这印证了该行业向靶向α疗法的转型。

同时，同位素生产技术和放射性药物供应链的进步正在降低对传统核子反应炉的依赖。为了解决先进治疗所需的α发射体供不应求和国际分销不稳定的问题，对粒子加速器等替代生产技术的投资显着增加。近期欧洲基础设施的资金筹措凸显了这个结构性转变。 2024年9月，PanTera NV宣布获得9,300万欧元的A轮资金筹措，用于在比利时早期建立一座商业规模的锕-225生产厂。这种产能的提升对于确保稳定同位素的供应、降低物流风险以及实现新型核医药物的永续商业化至关重要。

市场挑战

全球核子医学市场发展面临的主要障碍之一是供应链的持续不稳定，尤其是在短寿命放射性同位素的生产方面。与标准药品不同，钼-99等同位素由于其放射性崩坏迅速而无法储存，因此需要一个完美无缺的「即时」全球配送系统。目前，这个配送网络依赖数量日益减少的研究用核子反应炉，这些反应器老化严重，结构故障和计划外维护的风险也越来越高。如果这些关键设施运作，诊断试剂短缺将迫使医疗机构推迟或取消检查，直接影响患者数量和收入来源。

这种运作可靠性的缺失严重限制了市场成长，削弱了医院管理者和医生的信心。面对不稳定的供应计划，医疗专业人员可能会将患者转介至其他诊断方式，例如CT和MRI，减缓核医影像技术的普及。这种依赖性在主要市场尤为突出。例如，核子医学与分子影像学会（SNMMI）2024年的报告显示，美国超过80%的Technetium-99m供应依赖海外进口，这使得该产业极易受到国际物流中断的影响。

市场趋势

放射性药物在神经病学领域的应用不断扩展，正在改变整个市场模式。这主要得益于阿兹海默症缓解疾病疗法的出现，而这些疗法需要精准的分子影像技术。这一趋势不再局限于传统的肿瘤治疗领域，而是依赖β-淀粉样蛋白正子断层扫描（PET）检测在患者合格和治疗后续观察的关键作用。这种临床需求导致诊断量激增，也印证了非肿瘤应用领域的拓展。例如，Fierce Pharma在2025年2月发布的报告显示，卫材公司（Eisai）在美国2024年第四季的β-淀粉样蛋白PET检测量增加了45%，这表明治疗方案的普及与诊断需求之间存在直接关联。

同时，随着相关人员寻求透过稳健、一体化的基础设施来降低供应链风险，合约研发生产机构（CDMO）的重要性日益凸显，并正成为产业结构的重要组成部分。领先的医疗机构和投资者越来越重视能够确保可靠的复杂同位素生产和全球供应的垂直整合型製造商。这种重视体现在近期的财务活动中，例如Curium Pharma在2025年11月宣布已完成一项资本重组协议，公司估值约为70亿美元，凸显了该公司对其可扩展生产能力的高度重视。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球核子医学市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（诊断性核子医学和治疗性核子医学）
  • 透过诊断性核子医学（SPECT 和 PET 放射性药物）
  • 治疗性核子医学（β射线发射体、α射线发射体和近距离放射治疗同位素）
  • 依应用领域（肿瘤科、心臟科、神经科、其他）
  • 依最终使用者（医院/诊所、诊断中心、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美核子医学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲核子医学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区核子医学市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲核子医学市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美核子医学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球核子医学市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Cardinal Health, Inc.
• Curium SAS
• GE Healthcare, Inc.
• Novartis AG
• Lantheus Medical Imaging, Inc.
• Bayer AG
• Bracco Imaging SpA
• Nordion Inc.
• Isotopia Molecular Imaging Limited
• NorthStar Medical Radioisotopes, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Nuclear Medicine industry is projected to expand significantly, rising from USD 10.19 Billion in 2025 to USD 19.34 Billion by 2031, achieving a CAGR of 11.27%. This specialized medical field utilizes radiopharmaceuticals to evaluate physiological processes and manage diseases through targeted molecular interventions. The market's foundational growth is driven by a rapidly aging global demographic and an associated increase in chronic illnesses, such as cancer and cardiovascular diseases, which necessitate high-precision diagnostic and therapeutic capabilities. These epidemiological and demographic trends guarantee a lasting demand for nuclear imaging and radionuclide therapies, distinguishing them from temporary market fads.

Despite this potential, the sector encounters major obstacles related to supply chain reliability, specifically the continuous availability of short-lived radioisotopes essential for diagnostics. Producing these vital materials depends heavily on a small number of aging research reactors, leaving the supply chain exposed to logistical interruptions. Highlighting this fragility, Nuclear Medicine Europe reported that unexpected reactor maintenance in late 2024 was expected to result in supply shortages reaching 40% for critical diagnostic isotope generators, underscoring the instability of the global distribution framework.

Market Driver

The swift growth of theranostics and precision medicine serves as a major accelerator for market expansion, transitioning the industry from solely diagnostic imaging to comprehensive therapeutic strategies. This methodology, which combines diagnostic biomarkers with therapeutic radioisotopes, has achieved significant commercial success, especially in oncology for managing prostate and neuroendocrine tumors. The financial strength of this trend is demonstrated by the performance of top radioligand therapies; for example, Novartis revealed in its Q3 2024 results that global revenue for its prostate cancer treatment, Pluvicto, hit $386 million in that quarter, marking a 50% increase year-over-year. Accordingly, leading pharmaceutical companies are rapidly investing in this sector, as seen in Bristol Myers Squibb's acquisition of RayzeBio for roughly $4.1 billion in February 2024 to secure an actinium-based radiopharmaceutical pipeline, confirming the industry's shift toward targeted alpha therapies.

Concurrently, advancements in isotope production and the radiopharmaceutical supply chain are developing to reduce the historic dependence on older nuclear reactors. To counter the instability of global distribution and the shortage of alpha-emitters needed for advanced therapies, there is a notable increase in investments toward alternative manufacturing techniques, such as particle accelerators. This structural evolution is highlighted by recent funding for European infrastructure; PanTera NV announced in September 2024 that it secured €93 million in Series A funding to fast-track the creation of a commercial-scale Actinium-225 production plant in Belgium. Such enhancements in production capacity are vital for guaranteeing a consistent isotope supply, thereby diminishing logistical risks and enabling the sustainable commercial launch of novel nuclear medicine agents.

Market Challenge

The central hurdle obstructing the Global Nuclear Medicine market's progress is the ongoing volatility of its supply chain, specifically concerning the manufacture of short-lived radioisotopes. In contrast to standard drugs, isotopes like Molybdenum-99 cannot be stored due to rapid radioactive decay, requiring a flawless "just-in-time" global delivery system. This network currently depends on a shrinking group of aging research reactors that are increasingly susceptible to structural breakdowns and unplanned maintenance. When these essential facilities become inoperative, the resulting shortage of diagnostic agents compels healthcare providers to delay or annul procedures, directly impacting patient volume and revenue streams.

This lack of operational reliability significantly restricts market growth by undermining the trust of hospital administrators and physicians. Confronted with erratic supply schedules, medical practitioners may redirect patients toward other diagnostic methods such as CT or MRI, effectively slowing the uptake of nuclear imaging technologies. The gravity of this reliance is particularly severe in key markets; for instance, the Society of Nuclear Medicine and Molecular Imaging reported in 2024 that the United States depended on foreign imports for more than 80% of its Technetium-99m supply, rendering the industry extremely susceptible to disruptions in international logistics.

Market Trends

The extension of radiopharmaceutical utility into neurology is significantly transforming the market, fueled by the release of disease-modifying Alzheimer's treatments that require accurate molecular imaging. Departing from the sector's traditional focus on oncology, this trend relies on the essential function of amyloid-beta positron emission tomography (PET) scans for qualifying patients and monitoring treatment. This clinical requirement has triggered an immediate rise in diagnostic volumes, confirming the movement toward non-cancer applications. As an illustration, Fierce Pharma reported in February 2025 that Eisai observed a 45% surge in amyloid beta PET testing volumes within the United States during the last quarter of 2024, showing a direct link between therapeutic uptake and diagnostic demand.

At the same time, the increasing importance of Contract Development and Manufacturing Organizations (CDMOs) is becoming a fundamental component of the industry structure, as stakeholders aim to reduce supply chain risks through robust, consolidated infrastructure. Major healthcare organizations and investors are placing higher value on vertically integrated manufacturers capable of ensuring reliable complex isotope production and global delivery. This appreciation is reflected in recent financial activities; for example, Curium Pharma announced in November 2025 that it completed a recapitalization deal valuing the enterprise at roughly $7 billion, highlighting the premium attached to scalable manufacturing competencies.

Key Market Players

• Cardinal Health, Inc.
• Curium SAS
• GE Healthcare, Inc.
• Novartis AG
• Lantheus Medical Imaging, Inc.
• Bayer AG
• Bracco Imaging S.p.A
• Nordion Inc.
• Isotopia Molecular Imaging Limited
• NorthStar Medical Radioisotopes, LLC

Report Scope

In this report, the Global Nuclear Medicine market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nuclear Medicine market, By Type

• Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine

Nuclear Medicine market, By Diagnostic Nuclear Medicine

• SPECT & PET Radiopharmaceuticals

Nuclear Medicine market, By Therapeutic Nuclear Medicine

• Beta Emitters
• Alpha Emitters & Brachytherapy Isotopes

Nuclear Medicine market, By Application

• Oncology
• Cardiology
• Neurology
• Others

Nuclear Medicine market, By End User

• Hospitals & Clinics
• Diagnostic Centers
• Academic & Research Institutions
• Others

Nuclear Medicine market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine market.

Available Customizations:

Global Nuclear Medicine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nuclear Medicine market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine)
  • 5.2.2. By Diagnostic Nuclear Medicine (SPECT & PET Radiopharmaceuticals)
  • 5.2.3. By Therapeutic Nuclear Medicine (Beta Emitters, Alpha Emitters & Brachytherapy Isotopes)
  • 5.2.4. By Application (Oncology, Cardiology, Neurology, Others)
  • 5.2.5. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Nuclear Medicine market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Diagnostic Nuclear Medicine
  • 6.2.3. By Therapeutic Nuclear Medicine
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nuclear Medicine market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Diagnostic Nuclear Medicine
      • 6.3.1.2.3. By Therapeutic Nuclear Medicine
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Nuclear Medicine market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Diagnostic Nuclear Medicine
      • 6.3.2.2.3. By Therapeutic Nuclear Medicine
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Nuclear Medicine market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Diagnostic Nuclear Medicine
      • 6.3.3.2.3. By Therapeutic Nuclear Medicine
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Nuclear Medicine market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Diagnostic Nuclear Medicine
  • 7.2.3. By Therapeutic Nuclear Medicine
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nuclear Medicine market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnostic Nuclear Medicine
      • 7.3.1.2.3. By Therapeutic Nuclear Medicine
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Nuclear Medicine market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnostic Nuclear Medicine
      • 7.3.2.2.3. By Therapeutic Nuclear Medicine
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Nuclear Medicine market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnostic Nuclear Medicine
      • 7.3.3.2.3. By Therapeutic Nuclear Medicine
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Nuclear Medicine market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Diagnostic Nuclear Medicine
      • 7.3.4.2.3. By Therapeutic Nuclear Medicine
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Nuclear Medicine market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Diagnostic Nuclear Medicine
      • 7.3.5.2.3. By Therapeutic Nuclear Medicine
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Nuclear Medicine market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Diagnostic Nuclear Medicine
  • 8.2.3. By Therapeutic Nuclear Medicine
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nuclear Medicine market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnostic Nuclear Medicine
      • 8.3.1.2.3. By Therapeutic Nuclear Medicine
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Nuclear Medicine market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnostic Nuclear Medicine
      • 8.3.2.2.3. By Therapeutic Nuclear Medicine
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Nuclear Medicine market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnostic Nuclear Medicine
      • 8.3.3.2.3. By Therapeutic Nuclear Medicine
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Nuclear Medicine market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnostic Nuclear Medicine
      • 8.3.4.2.3. By Therapeutic Nuclear Medicine
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Nuclear Medicine market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnostic Nuclear Medicine
      • 8.3.5.2.3. By Therapeutic Nuclear Medicine
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Nuclear Medicine market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Diagnostic Nuclear Medicine
  • 9.2.3. By Therapeutic Nuclear Medicine
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nuclear Medicine market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnostic Nuclear Medicine
      • 9.3.1.2.3. By Therapeutic Nuclear Medicine
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Nuclear Medicine market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnostic Nuclear Medicine
      • 9.3.2.2.3. By Therapeutic Nuclear Medicine
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Nuclear Medicine market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnostic Nuclear Medicine
      • 9.3.3.2.3. By Therapeutic Nuclear Medicine
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Nuclear Medicine market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Diagnostic Nuclear Medicine
  • 10.2.3. By Therapeutic Nuclear Medicine
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nuclear Medicine market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnostic Nuclear Medicine
      • 10.3.1.2.3. By Therapeutic Nuclear Medicine
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Nuclear Medicine market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnostic Nuclear Medicine
      • 10.3.2.2.3. By Therapeutic Nuclear Medicine
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Nuclear Medicine market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnostic Nuclear Medicine
      • 10.3.3.2.3. By Therapeutic Nuclear Medicine
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nuclear Medicine market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cardinal Health, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Curium SAS
• 15.3. GE Healthcare, Inc.
• 15.4. Novartis AG
• 15.5. Lantheus Medical Imaging, Inc.
• 15.6. Bayer AG
• 15.7. Bracco Imaging S.p.A
• 15.8. Nordion Inc.
• 15.9. Isotopia Molecular Imaging Limited
• 15.10. NorthStar Medical Radioisotopes, LLC

16. Strategic Recommendations

17. About Us & Disclaimer